Zydus VC Arm Invests In Canada’s Feldan Therapeutics

Zydus Lifesciences on Thursday said its venture capital arm, Zynext Ventures USA LLC, has invested in Canada-based Feldan Therapeutics, a company developing treatments based on intracellular delivery of therapeutics.

Zynext Ventures identifies and backs early- and growth-stage healthcare companies with financial support, strategic guidance, and industry expertise, the company said in an exchange filing.

Feldan has created a special Shuttle peptide technology that helps deliver biomolecules directly into cells. Its main drug candidate, FLD-103, is designed to be applied directly to basal cell carcinoma tumors, where it uses the Shuttle peptide to deliver a Hedgehog inhibitor straight to the cancer cells.